Home » Stocks » SLRX

Salarius Pharmaceuticals, Inc. (SLRX)

Stock Price: $1.28 USD -0.07 (-5.19%)
Updated Mar 5, 2021 4:00 PM EST - Market closed
After-hours: $1.36 +0.08 (6.25%) Mar 5, 7:58 PM
Market Cap 31.19M
Revenue (ttm) 4.79M
Net Income (ttm) -7.47M
Shares Out 17.97M
EPS (ttm) -0.66
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day March 5
Last Price $1.28
Previous Close $1.35
Change ($) -0.07
Change (%) -5.19%
Day's Open 1.37
Day's Range 1.17 - 1.40
Day's Volume 2,645,470
52-Week Range 0.56 - 3.50

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 2 days ago

HOUSTON, March 03, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pedia...

Benzinga - 1 week ago

A slew of healthcare stocks is moving on Wednesday in reaction to company-specific catalysts. Sunesis Rises On Hopes of Completion of Merger Deal: Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS),...

Other stocks mentioned: PRAH, PSTX, SNSS
GlobeNewsWire - 1 week ago

HOUSTON, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediat...

GlobeNewsWire - 2 weeks ago

Seclidemstat safety profile affirmed; Recommended Phase 2 dose established

GlobeNewsWire - 2 weeks ago

HOUSTON, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, LLC, a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, sol...

GlobeNewsWire - 1 month ago

HOUSTON, Jan. 21, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediat...

GlobeNewsWire - 1 month ago

HOUSTON, Jan. 15, 2021 (GLOBE NEWSWIRE) -- Salarius Pharm aceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pedia...

GlobeNewsWire - 1 month ago

HOUSTON, Jan. 13, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediat...

GlobeNewsWire - 2 months ago

HOUSTON, Dec. 22, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, sol...

GlobeNewsWire - 2 months ago

HOUSTON, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediat...

GlobeNewsWire - 2 months ago

HOUSTON, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediat...

GlobeNewsWire - 3 months ago

HOUSTON, Nov. 17, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediat...

Seeking Alpha - 3 months ago

Salarius Pharmaceuticals, Inc. (SLRX) CEO David Arthur on Q3 2020 Results - Earnings Call Transcript

GlobeNewsWire - 3 months ago

Conference Call and Live Audio Webcast Scheduled for Today, November 11, 2020, at 4:30 p.m. ET Conference Call and Live Audio Webcast Scheduled for Today, November 11, 2020, at 4:30 p.m. ET

GlobeNewsWire - 4 months ago

Conference Call and Live Audio Webcast Scheduled for Wednesday, November 11, at 4:30 p.m. ET Conference Call and Live Audio Webcast Scheduled for Wednesday, November 11, at 4:30 p.m. ET

GlobeNewsWire - 4 months ago

HOUSTON, Oct. 13, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, LLC, a clinical-stage oncology company targeting cancers caused by dysregulated gene expression, announced today that its C...

GlobeNewsWire - 5 months ago

Presentations Will Highlight Corporate and Clinical Progress Presentations Will Highlight Corporate and Clinical Progress

GlobeNewsWire - 6 months ago

Webcast presentation scheduled for Tuesday, September 1, 2020 Webcast presentation scheduled for Tuesday, September 1, 2020

Seeking Alpha - 6 months ago

Salarius Pharmaceuticals, Inc. (SLRX) CEO David Arthur on Q2 2020 Results - Earnings Call Transcript

GlobeNewsWire - 6 months ago

Company Closes $6.2M Public Offering and Expands Clinical Program to Include Ewing-Related Sarcomas

GlobeNewsWire - 7 months ago

Conference Call and Live Audio Webcast Scheduled for Wednesday, August 12, at 4:30 p.m. ET Conference Call and Live Audio Webcast Scheduled for Wednesday, August 12, at 4:30 p.m. ET

GlobeNewsWire - 7 months ago

New Patent Protects Composition of Matter and Methods of Use Through At Least August 2032 New Patent Protects Composition of Matter and Methods of Use Through At Least August 2032

GlobeNewsWire - 7 months ago

HOUSTON, July 30, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting cancers caused by dysregulated gene expression, today an...

GlobeNewsWire - 7 months ago

HOUSTON, July 29, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting cancers caused by dysregulated gene expression, today ...

GlobeNewsWire - 7 months ago

Pre-Clinical Data and Early Clinical Observations Support Company’s Decision to Research Seclidemstat as a Potential Treatment in Ewing-Related Sarcomas Pre-Clinical Data and Early Clinical Ob...

Benzinga - 7 months ago

A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company’s future growth prospects.

Other stocks mentioned: BIIB, CHRS, GEN, LXRX
Seeking Alpha - 9 months ago

Salarius Pharmaceuticals, Inc. (SLRX) CEO David Arthur on Q1 2020 Results - Earnings Call Transcript

GlobeNewsWire - 9 months ago

Seclidemstat Advances Dose Escalation in Phase 1/2 Ewing Sarcoma Clinical Trial; On Track to Report Early Data in 2020

GlobeNewsWire - 10 months ago

Board of Directors Seeks the Election of Jonathan Lieber, Industry Veteran with Deep Financial and Wall Street Expertise, as a New, Independent Director Board of Directors Seeks the Election o...

GlobeNewsWire - 1 year ago

European Patent Office Satisfied Patent Application Meets All Requirements

GlobeNewsWire - 1 year ago

HOUSTON, Feb. 11, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting cancers caused by dysregulated gene expression, today an...

GlobeNewsWire - 1 year ago

HOUSTON, Feb. 07, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancer, today announced the pri...

GlobeNewsWire - 1 year ago

Seclidemstat Modulates Tumor Microenvironment to Help Genetically Mutated Cancer Types Overcome Resistance to Checkpoint Inhibitors in Preclinical Study

About SLRX

Salarius Pharmaceuticals a clinical-stage biotechnology company, develops epigenetic-based cancer treatments. The company's lead candidate is Seclidemstat (SP-2577), which is in Phase I/II clinical trial for the treatment of advanced solid tumors, including prostate, breast, and ovarian cancers, as well as Ewing sarcoma. Salarius Pharmaceuticals, Inc. has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to d... [Read more...]

Industry
Biotechnology
CEO
David Arthur
Employees
7
Stock Exchange
NASDAQ
Ticker Symbol
SLRX
Full Company Profile

Financial Performance

In 2019, SLRX's revenue was $3.47 million, an increase of 77.57% compared to the previous year's $1.95 million. Losses were -$6.94 million, 315.4% more than in 2018.

Financial Statements

Analyst Forecasts

According to 2 analysts, the average rating for SLRX stock is "Strong Buy." The 12-month stock price forecast is 4.43, which is an increase of 246.09% from the latest price.

Price Target
$4.43
(246.09% upside)
Analyst Consensus: Strong Buy